Evidence map›Paper›PMID 29696080›Full record

ArticleJournal of extracellular vesicles2018

Therapeutic effects of serum extracellular vesicles in liver fibrosis.

Li Chen, Ruju Chen, Sherri Kemper, Min Cong, Hong You, David R Brigstock

Open access · goldAbstract read
In one paragraph

Article in Journal of extracellular vesicles, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.

0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
4.4field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

66 citing papers in PubMed, 112 citations in OpenAlex.

  1. Circulating Liver-Derived and CD36Journal of extracellular vesicles · 2026
    Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Extracellular vesicles: emerging therapeutic agents for liver fibrosis.Extracellular vesicles and circulating nucleic acids · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. MicroRNAs and Nonalcoholic Steatohepatitis: A Review.International journal of molecular sciences · 2023
    Review

6 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 2 countries.

Li ChenCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Ruju ChenCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Sherri KemperCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.
Min CongLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China.
Hong YouLiver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine in Liver Cirrhosis, National Clinical Research Center of Digestive Diseases, Beijing, China.
David R BrigstockCenter for Clinical and Translational Research, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USA.ORCID 0000-0001-8651-6486
Nationwide Children's Hospital · USCapital Medical University · CN

Funding

UCD Mutant Mouse Regional Resource CenterU42OD012210 · OD · UNIVERSITY OF CALIFORNIA AT DAVIS · PI KC KENT LLOYD · 2012 to 2026
$29.2M
MicroRNA regulation of CTGF in hepatic stellate cellsR01AA021276 · NIAAA · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BRIGSTOCK, DAVID R · 2012 to 2016
$1.6M
Exosome platforms for assessment and therapy of chronic liver diseaseR21AA023626 · NIAAA · RESEARCH INST NATIONWIDE CHILDREN'S HOSP · PI BRIGSTOCK, DAVID R · 2015 to 2016
$392k
NIAAA NIH HHS R01 AA021276NIAAA NIH HHS R21 AA023626NIH HHS U42 OD012210
6 · The paper itself

Abstract

The lack of approved therapies for hepatic fibrosis seriously limits medical management of patients with chronic liver disease. Since extracellular vesicles (EVs) function as conduits for intercellular molecular transfer, we investigated if EVs from healthy individuals have anti-fibrotic properties. Hepatic fibrogenesis or fibrosis in carbon tetrachloride (CCl

Indexed as

anti-fibrotic therapyExosomefibrogenesisfibrosishepatic stellate cellhepatocytemicroRNA

Identifiers

PMID29696080
PMCPMC5912192
OpenAlexW2800337771

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.